01 January 2003
A trial of objective comparison of quality of life between chronic renal failure patients treated with hemodialysis and renal transplantation.
Tomasz Wesołowski, Piotr SzyberAnn Transplant 2003; 8(2): 48-54 :: ID: 142803
Abstract
An interesting issue is a hemodialysis patients' and renal transplant recipients'subjective assessment of their QOL as a basic sociological criterion of treatment efficacy. The aim ofthe study is an estimation and comparison of QOL between these patients with a questionnaire the WHOQOL-100as a trial of objective comparison of quality of life between these two groups of patients. A methodof diagnostic probing with use of the questionnaire in its Polish language version was employed. A numberof 400 (in total) questionnaires (200 in each group) were given to randomly chosen CRF patients. Fulfilledquestionnaires were obtained from 144 (36%) patients who underwent the study: 61 from HD group (30.5%)and 83 from TX group (41.5%). RESULTS: Regarding sex and education, differences between groups were notsignificant statistically. As for the age and marital status, differences between groups were significant(p = 2.5 E-13 and p = 0.0045 respectively). In the both groups, (living from the health pension fromthe Government Health Insurance--ZUS) was overwhelming (HD--96.12% and TX--77.11%). A difference in amountof 'having a job' patients between groups was not significant (p = 0.153). In QOL estimation, significantdifferences between group HD and TX were assessed in overall QOL (p = 1.04 E-07), in physical domain(p = 0.00053) and social relationships domain (p = 0.0004). In the rest of domains, scores were approximatein both groups and did not differ significantly. Comparing facets scores, some significant differencesbetween HD and TX groups were observed: pain and discomfort (p = 0.032), energy and fatigue (p = 2.2E-05), positive feelings (p = 0.002), body image and appearance (p = 0.010), mobility (p = 0.031), activitiesof daily living (p = 0.036), working capacity (p = 0.008), personal relationships (p = 0.004), sexualactivity (p = 7.3 E-06) and transport (p = 0.036). Higher scores were stated in TX group in all of thosefacets excluding body image and appearance and pain and discomfort. CONCLUSIONS: 1) TX patients QOL isbetter than HD patients' in domains: overall, physical, social relationships and environment and alsoin facets: pain and discomfort, energy and fatigue, positive feelings, mobility, activities of dailyliving, working capacity, personal relationships, sexual activity and transport. 2) In the facet bodyimage and appearance, TX patients' QOL is worse than HD patients'. 3) The results point out the WHOQOL-100to be a useful and reliable instrument for measuring quality of life in different populations makingpossible to compare it objectively.
In Press
Original article
Steroid Use in ABO-Incompatible Kidney Transplants: Withdrawal vs MaintenanceAnn Transplant In Press; DOI: 10.12659/AOT.947747
Original article
Intra-Arterial Contrast-Enhanced Ultrasound for Transcatheter Thrombolysis in Post-Transplant Hepatic Arter...Ann Transplant In Press; DOI: 10.12659/AOT.947500
Original article
Early Atropine Protocol Enhances Dobutamine Stress Echocardiography in End-Stage Liver Disease: A Practical...Ann Transplant In Press; DOI: 10.12659/AOT.950166
Most Viewed Current Articles
15 Aug 2023 : Review article 7,349
Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ TransplantationDOI :10.12659/AOT.939750
Ann Transplant 2023; 28:e939750
03 Jan 2023 : Original article 7,205
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...DOI :10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
16 May 2023 : Original article 7,029
Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...DOI :10.12659/AOT.939258
Ann Transplant 2023; 28:e939258
28 May 2024 : Original article 6,629
Effect of Dexmedetomidine Combined with Remifentanil on Emergence Agitation During Awakening from Sevoflura...DOI :10.12659/AOT.943281
Ann Transplant 2024; 29:e943281